Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone. This study will also investigate patient benefit, safety and whether or not vinflunine shrinks or slows the growth of the cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pierre Fabre Medicament
• Collaborator: Bristol-Myers Squibb
• Treatments: Vinblastine

Criteria

Inclusion Criteria:

• Bladder cancer

• Progressed after 1st line platinum-chemotherapy

• >= 18 years old

• Adequate hematologic, hepatic & renal function

Exclusion Criteria:

• CNS disease

• Moderate neuropathy

• More than 1 previous chemotherapy